Good
Partially Aligned
Patient Risk:
Low
Summary
All three claims about initial 2015 FDA launch indications and mutation types are about “initial 2015 indications,” but the supplied prescribing information excerpts do not contain any statements about 2015 launch/initial approvals. Mutation specificity (exon 19 deletions and exon 21 L858R) is supported for current indications, but the timeline/“initial 2015” aspect is unsupported from the provided label text.
Category Scores
Accurate Statements
The initial 2015 indications for Tagrisso focus on patients with non-small cell lung cancer (NSCLC) with an EGFR mutation.
Indications in the provided label are for adult patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations (e.g., Sections 1.1–1.4).
For Tagrisso’s initial 2015 FDA launch, the indication is associated with NSCLC tumors that have an EGFR exon 19 deletion or an EGFR exon 21 L858R substitution mutation.
The provided label specifies EGFR exon 19 deletions or exon 21 L858R mutations for multiple NSCLC indications (Sections 1.1–1.4).
Unsupported Statements
Tagrisso (osimertinib) was initially approved in the United States in 2015.
The provided prescribing information excerpts do not include any approval-year or “initial approval” timeline information.
The initial 2015 indications for Tagrisso focus on patients with non-small cell lung cancer (NSCLC) with an EGFR mutation.
The provided prescribing information excerpts do not state that these indications were the “initial 2015” indications; they only list current indications.
For Tagrisso’s initial 2015 FDA launch, the indication is associated with NSCLC tumors that have an EGFR exon 19 deletion or an EGFR exon 21 L858R substitution mutation.
While the mutation criteria are consistent with current indications in the provided label, the excerpt does not provide any linkage to a “2015 FDA launch” or “initial” indication set.
Contradictions
Important Omissions
No label-supported statement regarding the 2015 approval timing or what specifically constituted the “initial 2015” FDA indication(s).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims primarily concern historical approval/indication timing. The only safety-relevant content (drug name/active ingredient and mutation types) does not conflict with the provided label; however, the missing timeline support limits label-consistency accuracy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
The provided label excerpts do not support any “initial 2015 approval/launch” timeline claims, even though the EGFR exon 19/exon 21 L858R mutation criteria match current indications.
Suggested Improvement
Remove or revise the “initial 2015 FDA launch/initial approval in 2015” language unless supported by a label section that explicitly states approval timing; instead, state only the mutation-based indication criteria as shown in Sections 1.1–1.5.